@7newsaustralia's Ozempic blindness claims fact-checked

What did @7newsaustralia actually say?

The clip claims that weight loss drugs like Ozempic and Mounjaro can "seriously damage your eyesight" and that their active ingredients "cause inflammation and block blood flow to the optic nerve, leading to severe and sometimes permanent blindness." That framing is more alarming than the underlying research warrants. The word "cause" is doing a lot of heavy lifting here, and the science does not support that word yet.

The segment does acknowledge that "more research is needed," which is accurate. But by then, most viewers have already absorbed the headline: these drugs blind people. That sequencing matters.

Does the science back this up?

Partially, and with important caveats. There is a real study behind this story, but it does not prove causation. The research most likely referenced is Hathaway et al. (2024, JAMA Ophthalmology), which found a statistically significant association between semaglutide use and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), a condition involving reduced blood flow to the optic nerve that can cause vision loss.

• The study was retrospective, meaning it looked backward at medical records, not a controlled trial.
• NAION is already rare. The absolute risk increase was small, even if the relative risk looked significant.
• The study population was largely people with type 2 diabetes or obesity, groups already at elevated cardiovascular and vascular risk.
• Tirzepatide (Mounjaro) was not the focus of the Hathaway study. Lumping it in is an extrapolation.

A separate analysis from Azoulay et al. (2024, Neurology) found no significant association between GLP-1 use and NAION in a Canadian cohort. So the evidence is genuinely mixed right now.

What did they get wrong (or right)?

They got the existence of a safety signal right. There is a legitimate scientific conversation happening about GLP-1 drugs and optic nerve health. Credit where it is due. But several things went wrong in the framing.

First, saying these drugs "cause inflammation and block blood flow" presents a proposed mechanism as established fact. Researchers have hypothesized this pathway, but it has not been confirmed in human studies. Second, the clip attributes the same risk to Mounjaro (tirzepatide) without direct evidence. Tirzepatide is a GIP/GLP-1 dual agonist with a distinct pharmacological profile, and extrapolating findings from semaglutide studies to it is not scientifically sound. Third, "sometimes permanent blindness" while technically possible with NAION is presented in a way that inflates the likely outcome for average users. Most patients with NAION retain partial vision.

Calling this "seriously damage your eyesight" without quantifying absolute risk is how you turn a preliminary signal into a viral panic.

What should you actually know?

If you are using semaglutide or any GLP-1 drug, this is worth knowing about, but not worth stopping your medication over without talking to your prescriber. NAION is rare in the general population, estimated at around 2 to 10 cases per 100,000 people per year. The Hathaway 2024 study found roughly a 4-fold increased relative risk in semaglutide users with type 2 diabetes and a roughly 7-fold increase in those using it for obesity, but these were in populations with existing vascular risk factors.

• If you notice sudden vision changes, blurring, or vision loss in one eye, seek urgent medical care regardless of what medications you are on. That is true for everyone.
• The FDA has not issued a label change or safety warning specific to NAION as of mid-2024. That may change as more data accumulates.
• People with a prior history of NAION or significant optic nerve risk factors should have a specific conversation with their ophthalmologist and prescribing clinician before starting or continuing GLP-1 therapy.

The real story here is that a rare but serious adverse event signal has emerged and needs rigorous follow-up. That is genuinely newsworthy. It just did not need the word "blindness" in the hashtags to be worth covering.